AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28917229 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg [13C10] retinyl acetate capsule (reference dose) with PBG
Number of subjects: 37
Study 28917229 — intervention group
Group type: COMPARATOR
Intervention: 1 mg [13C10] retinyl acetate capsule (reference dose) with LG
Number of subjects: 37
Study 25927483 — intervention group
Group type: COMPARATOR
Intervention: Spiromax after PIL training
Number of subjects: 200
Study 25927483 — intervention group
Group type: COMPARATOR
Intervention: Spiromax after enhanced training
Number of subjects: 200
Study 25927483 — intervention group
Group type: COMPARATOR
Intervention: Spiromax
Number of subjects: 200
Study 25927483 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 200
Study 25927483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices after enhanced training
Number of subjects: 200
Study 23361105 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 115
Study 23361105 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 140
Number of subjects: 115
Study 23361105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 23361105 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA and HOE 140
Number of subjects: 115
Study 23361105 — intervention group
Group type: COMPARATOR
Intervention: EACA, HOE 140, and Placebo
Number of subjects: 115
Study 21165692 — intervention group
Group type: EXPERIMENTAL
Intervention: Group motivational interviewing (MI)
Number of subjects: 203
Study 21165692 — intervention group
Group type: COMPARATOR
Intervention: Group health promotion program
Number of subjects: 203
Study 19674176 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on self‐completed instruments
Number of subjects: 53
Study 19674176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 16489694 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ritodrine sustained release capsules three times a day (study group, n=62)
Number of subjects: 120
Study 16489694 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n=58)
Number of subjects: 120
Study 14749094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (15 mg PO per day for 2 weeks followed by 30 mg PO per day for 2 weeks)
Number of subjects: 17
Study 14749094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (N=5)
Number of subjects: 17
Study 14749094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=6)
Number of subjects: 17
Study 11338300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral lidocaine delivery system (LDS)
Number of subjects: 20
Study 11338300 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine-gel preparation (BGP)
Number of subjects: 20
Study 11338300 — intervention group
Group type: COMPARATOR
Intervention: Non-anesthetic control
Number of subjects: 20
Study 9390107 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Number of subjects: 9
Study 9390107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8197085 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated courses of hyperbaric oxygenation (HBO)
Number of subjects: 39
Study 8197085 — intervention group
Group type: EXPERIMENTAL
Intervention: Three courses of HBO therapy administered at 4 months intervals
Number of subjects: 39
Study 8197085 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 IDDM patients, no treatment)
Number of subjects: 39
Study 30093449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib tablets (60 mg/m2/dose × 7 days), irinotecan (50 mg/m2/dose i.v. × 5 days), and temozolomide (100 mg/m2/dose orally × 5 days)
Number of subjects: 32
Study 30093449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib oral solution (45 mg/m2)
Number of subjects: 32
Study 30093449 — intervention group
Group type: COMPARATOR
Intervention: Alisertib tablets (60 mg/m2/dose)
Number of subjects: 32
Study 26807896 — intervention group
Group type: EXPERIMENTAL
Intervention: Short breath-hold MR technique (CAIPIRINHA)
Number of subjects: 119
Study 26807896 — intervention group
Group type: COMPARATOR
Intervention: Long breath-hold MR technique (conventional VIBE)
Number of subjects: 119
Study 24227801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/mL TID pazopanib eye drops
Number of subjects: 70
Study 24227801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/mL TID pazopanib eye drops
Number of subjects: 70
Study 24227801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/mL QD pazopanib eye drops
Number of subjects: 70
Study 24227801 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 22361799 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews conducted by a faculty member and a student (n = 2,345)
Number of subjects: 3868
Study 22361799 — intervention group
Group type: COMPARATOR
Intervention: Interviews conducted by two faculty members (n = 1,523)
Number of subjects: 3868
Study 22361799 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer pairs structure (faculty vs. student involvement)
Number of subjects: 3868
Study 20434603 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injections followed by 12 weeks of postinjection task practice with FES
Number of subjects: 23
Study 20434603 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA injections followed by 12 weeks of postinjection task practice without FES
Number of subjects: 23
Study 18619772 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise withdrawal
Number of subjects: 40
Study 18619772 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued regular exercise)
Number of subjects: 40
Study 16874143 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training programme (Group A)
Number of subjects: 44
Study 16874143 — intervention group
Group type: COMPARATOR
Intervention: Generic instructions to maintain physical activity (Group B)
Number of subjects: 44
Study 12784106 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum 2 mg
Number of subjects: 3
Study 12784106 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 5 mg/day for 30 days
Number of subjects: 3
Study 12784106 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (acute) after target peak BAC of 0.10%
Number of subjects: 3
Study 12784106 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (8 h carryover)
Number of subjects: 3
Study 11166510 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness training activities
Number of subjects: 500
Study 11166510 — intervention group
Group type: COMPARATOR
Intervention: Standard approach typically used at the facility
Number of subjects: 500
Study 8780339 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS2) 30 g/d
Number of subjects: 57
Study 8780339 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS3) 30 g/d
Number of subjects: 57
Study 8780339 — intervention group
Group type: COMPARATOR
Intervention: Glucose (control)
Number of subjects: 57
Study 8780339 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS2 and RS3)
Number of subjects: 57
Study 1361083 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 mu/g) inhaled twice daily
Number of subjects: 40
Study 1361083 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 mu/g) inhaled 4 times daily
Number of subjects: 40
Study 3969207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (20 mg maximum daily dosage)
Number of subjects: 36
Study 3969207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (average dosage of 13 mg)
Number of subjects: 36
Study 3969207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 36
Study 31564314 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light–filtering IOL (AcrySof IQ SN60WF)
Number of subjects: 55
Study 31564314 — intervention group
Group type: COMPARATOR
Intervention: Violet light–filtering IOL (OptiBlue ZCB00V)
Number of subjects: 55
Study 29908888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized Fibrin Sealant (FS)
Number of subjects: 41
Study 29908888 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study 26953983 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch-and-wait treatment (nonoperative treatment)
Number of subjects: 118
Study 26953983 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision
Number of subjects: 118
Study 26953983 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and radiologic judgments of tumor response
Number of subjects: 118
Study 23937957 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-handed technique
Number of subjects: 52
Study 23937957 — intervention group
Group type: EXPERIMENTAL
Intervention: modified 2-handed technique
Number of subjects: 52
Study 23937957 — intervention group
Group type: COMPARATOR
Intervention: 1-handed technique
Number of subjects: 52
Study 23937957 — intervention group
Group type: COMPARATOR
Intervention: 2-handed technique vs 1-handed technique
Number of subjects: 52
Study 23937957 — intervention group
Group type: COMPARATOR
Intervention: modified 2-handed technique vs 1-handed technique
Number of subjects: 52
Study 22083073 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir intensification
Number of subjects: 50
Study 22083073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19237002 — intervention group
Group type: COMPARATOR
Intervention: low fat diet (1500kcal/day, 52% carbohydrates, 20% proteins, 27% fats)
Number of subjects: 74
Study 19237002 — intervention group
Group type: EXPERIMENTAL
Intervention: high fat and high protein diet (1507kcal/day, 38% carbohydrates, 26% proteins, 36% fats)
Number of subjects: 74
Study 18277740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Triumph with FlossAction brush head
Number of subjects: 50
Study 18277740 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Elite 7300 with full-size brush head
Number of subjects: 50
Study 18277740 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Elite 7300 with compact head
Number of subjects: 50
Study 16305725 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg daily for 6 weeks
Number of subjects: 51
Study 16305725 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide for treatment of clinical relapse
Number of subjects: 51
Study 11943525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative continuous epidural droperidol infusion (2.5 mg/day)
Number of subjects: 120
Study 11943525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative single IV injection of droperidol (2.5 mg)
Number of subjects: 120
Study 11943525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative IV injection of droperidol (2.5 mg) and postoperative continuous epidural droperidol infusion (2.5 mg/day)
Number of subjects: 120
Study 11943525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no droperidol)
Number of subjects: 120
Study 9808279 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-nerve SNC
Number of subjects: 82
Study 9808279 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface antidromic SNC
Number of subjects: 82
Study 9808279 — intervention group
Group type: COMPARATOR
Intervention: Statistical analysis
Number of subjects: 82
Study 9808279 — intervention group
Group type: COMPARATOR
Intervention: Absent sensory potentials
Number of subjects: 82
Study 8586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Step Cold Air Challenge (SSCACh)
Number of subjects: 28
Study 8586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Step Cold Air Challenge (MSCACh)
Number of subjects: 28
Study 8586132 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine Provocation
Number of subjects: 28
Study 2545721 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B treatment
Number of subjects: 12
Study 2545721 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 burn patients)
Number of subjects: 12
Study 775889 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 44
Study 775889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30819170 — intervention group
Group type: EXPERIMENTAL
Intervention: Support arm (referral to a weight management group)
Number of subjects: 1882
Study 30819170 — intervention group
Group type: COMPARATOR
Intervention: Advice arm (advice on health benefits of weight loss)
Number of subjects: 1882
Study 27966784 — intervention group
Group type: EXPERIMENTAL
Intervention: JASPER intervention
Number of subjects: 113
Study 27966784 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual waitlist
Number of subjects: 113
Study 26267727 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Number of subjects: 0
Study 26267727 — intervention group
Group type: COMPARATOR
Intervention: Vehicle spray
Number of subjects: 0
Study 24279904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacprodan® PL-20 (milk protein concentrate rich in phospholipids)
Number of subjects: 150
Study 24279904 — intervention group
Group type: COMPARATOR
Intervention: Phospholipid-free milk protein concentrate (placebo)
Number of subjects: 150
Study 24279904 — intervention group
Group type: COMPARATOR
Intervention: Inert rice starch (placebo)
Number of subjects: 150
Study 21347823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 20
Study 21347823 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Treatment (MED)
Number of subjects: 20
Study 21347823 — intervention group
Group type: COMPARATOR
Intervention: Lean subjects (Control)
Number of subjects: 20
Study 19108937 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mM sodium butyrate enema for 2 weeks
Number of subjects: 16
Study 19108937 — intervention group
Group type: COMPARATOR
Intervention: Saline enema for 2 weeks
Number of subjects: 16
Study 17207719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H)
Number of subjects: 0
Study 15365070 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler ultrasound-directed lymph node excisional biopsy
Number of subjects: 152
Study 15365070 — intervention group
Group type: COMPARATOR
Intervention: Standard excisional biopsy
Number of subjects: 152
Study 11343440 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 30 minutes of physical activity per week
Number of subjects: 2336
Study 11343440 — intervention group
Group type: COMPARATOR
Intervention: 30 or more minutes of physical activity per week
Number of subjects: 2336
Study 9599360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin
Number of subjects: 120
Study 9599360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac
Number of subjects: 120
Study 9599360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7973431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision-making based on symptoms and physical examination
Number of subjects: 1333
Study 7973431 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based diagnostic score
Number of subjects: 1333
Study 7973431 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous abdominal surgery
Number of subjects: 1333
Study 7973431 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of pain (colic/intermittent versus steady)
Number of subjects: 1333
Study 7973431 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal distension (yes versus no)
Number of subjects: 1333
Study 7973431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel sounds (abnormal versus normal)
Number of subjects: 1333
Study 2686411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 44
Study 2686411 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 44
Study 336052 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 100 mg 4 days a week for 4 months
Number of subjects: 27
Study 336052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29129554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Number of subjects: 0
Study 29129554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27692144 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (bronchodilator)
Number of subjects: 45
Study 27692144 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 45
Study 24659510 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised ECG criteria tool
Number of subjects: 62
Study 24659510 — intervention group
Group type: COMPARATOR
Intervention: Usual interpretation
Number of subjects: 62
Study 22152652 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency audiometer (frequency range: 125‐18,000 Hz)
Number of subjects: 47
Study 22152652 — intervention group
Group type: COMPARATOR
Intervention: Conventional audiometer (frequency range: 125‐12,000 Hz)
Number of subjects: 47
Study 22152652 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency audiometer
Number of subjects: 47
Study 22152652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of tinnitus
Number of subjects: 47
Study 20150346 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg)
Number of subjects: 220
Study 20150346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 17880770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast for 6 months
Number of subjects: 120
Study 17880770 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E for 6 months
Number of subjects: 120
Study 16151790 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation
Number of subjects: 0
Study 12138347 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir soft-gel capsules 1200 mg three times daily + zidovudine + optional lamivudine
Number of subjects: 18
Study 12138347 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 18
Study 12138347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (optional)
Number of subjects: 18
Study 10320157 — intervention group
Group type: EXPERIMENTAL
Intervention: Hextend
Number of subjects: 120
Study 10320157 — intervention group
Group type: COMPARATOR
Intervention: HES
Number of subjects: 120
Study 8675575 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD plus estrogen
Number of subjects: 19
Study 8675575 — intervention group
Group type: COMPARATOR
Intervention: LAD plus placebo
Number of subjects: 19
Study 1961669 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (underwent a specifically designed program lasting six months)
Number of subjects: 26
Study 1961669 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained group (no specific training program)
Number of subjects: 26
Study 1961669 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 boys of the same age)
Number of subjects: 26
Study 6123070 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam 1 mg (Noctamid)
Number of subjects: 60
Study 6123070 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 30858014 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH cleaning bundle intervention
Number of subjects: 11
Study 29524192 — intervention group
Group type: EXPERIMENTAL
Intervention: ChronoMag® (100 mg magnesium element)
Number of subjects: 12
Study 29524192 — intervention group
Group type: COMPARATOR
Intervention: Reference tablet (300 mg magnesium element)
Number of subjects: 12
Study 26917334 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical contact lenses (CLs)
Number of subjects: 281
Study 26917334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily-wear CLs
Number of subjects: 281
Study 26917334 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical CL fitting
Number of subjects: 281
Study 26917334 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses and soft lenses
Number of subjects: 281
Study 24184132 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg, once daily), Asunaprevir (200 mg, twice daily), BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 weeks
Number of subjects: 66
Study 24184132 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir, Asunaprevir, BMS-791325
Number of subjects: 66
Study 22971490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 20 ml 0.5% ropivacaine
Number of subjects: 135
Study 22971490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml saline)
Number of subjects: 135
Study 20010459 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 genotype group
Number of subjects: 29
Study 20010459 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5*1/*1+*1/*3 genotype group
Number of subjects: 29
Study 17610807 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct individual therapy (SLT working individually with a child)
Number of subjects: 161
Study 17610807 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect individual therapy (SLTA working individually with a child)
Number of subjects: 161
Study 17610807 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct group therapy (SLT working with a small group of children)
Number of subjects: 161
Study 17610807 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect group therapy (SLTA working with a small group of children)
Number of subjects: 161
Study 17610807 — intervention group
Group type: COMPARATOR
Intervention: Community-based SLT services (Control)
Number of subjects: 161
Study 17610807 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct therapy from an SLT
Number of subjects: 161
Study 17610807 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect group therapy
Number of subjects: 161
Study 17610807 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct individual therapy
Number of subjects: 161
Study 15175847 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-selection strategy with open access to DXA scans for 12 months
Number of subjects: 10
Study 15175847 — intervention group
Group type: COMPARATOR
Intervention: No case-finding strategy and no DXA scan access
Number of subjects: 10
Study 11915063 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (1% mepivacaine, 0.2% tetracaine, epinephrine 1:200,000) plus buprenorphine, 0.3 mg
Number of subjects: 60